Literature DB >> 16456109

Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications.

Evangelos D Michelakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16456109     DOI： 10.1161/01.RES.0000204572.65400.a5

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  25 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 2.  The role of mitochondria in pulmonary vascular remodeling.

Authors:  Peter Dromparis; Gopinath Sutendra; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2010-08-24       Impact factor: 4.599

3.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

4.  Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.

Authors:  Lloyd D Harvey; Stephen Y Chan
Journal:  J Physiol       Date:  2018-09-02       Impact factor: 5.182

Review 5.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

Review 6.  Mitochondrial and Metabolic Drivers of Pulmonary Vascular Endothelial Dysfunction in Pulmonary Hypertension.

Authors:  Qiujun Yu; Stephen Y Chan
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.

Authors:  Qiujun Yu; Yi-Yin Tai; Ying Tang; Jingsi Zhao; Vinny Negi; Miranda K Culley; Jyotsna Pilli; Wei Sun; Karin Brugger; Johannes Mayr; Rajeev Saggar; Rajan Saggar; W Dean Wallace; David J Ross; Aaron B Waxman; Stacy G Wendell; Steven J Mullett; John Sembrat; Mauricio Rojas; Omar F Khan; James E Dahlman; Masataka Sugahara; Nobuyuki Kagiyama; Taijyu Satoh; Manling Zhang; Ning Feng; John Gorcsan; Sara O Vargas; Kathleen J Haley; Rahul Kumar; Brian B Graham; Robert Langer; Daniel G Anderson; Bing Wang; Sruti Shiva; Thomas Bertero; Stephen Y Chan
Journal:  Circulation       Date:  2019-05-07       Impact factor: 29.690

8.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

9.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.

Authors:  Sebastien Bonnet; Gael Rochefort; Gopinath Sutendra; Stephen L Archer; Alois Haromy; Linda Webster; Kyoko Hashimoto; Sandra N Bonnet; Evangelos D Michelakis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-27       Impact factor: 11.205

10.  Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Authors:  Kari E Roberts; Ioana R Preston
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.